Open-label, single-arm, multiple-dose safety, titration, and pharmacokinetic study of AFREZZA® in pediatric subjects ages 4 to 17 years with type 1 diabetes mellitus

Recruiting
4 years - 12 years
All
1 Location

Brief description of study

The purpose of this research study is to measure how much of the study drug (Afrezza) gets into your blood
after a single dose and measure how well it works to control your blood sugar level. We also want to make sure
this study drug is safe for children and adolescents between 4 and 17 years old.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: type 1 diabetes mellitus
  • Age: 4 years - 12 years
  • Gender: All

Inclusion Criteria

Diagnosed with Type 1 diabetes for at least 1 year

Currently on multiple daily injections

No history of asthma

Updated on 04 Aug 2024. Study ID: 1810897000

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Zip Code
Please provide your 5-digit zip code
0 0 /250
Other language

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team